BlueRock Therapeutics news
BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced today the dose administration for the first patient in Canada in partnership with the University Health Network in a Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson’s disease. The purpose of the Ph1 clinical trial is to evaluate the safety, tolerability and
BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced the closeout of the first of two cohorts in its ongoing Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson’s disease. The purpose of the Ph1 clinical trial is to evaluate the safety, tolerability and preliminary efficacy of DA01 in patients with Parkinson
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly owned subsidiary of Bayer AG, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DA01 for advanced Parkinson’s disease (PD). DA01, BlueRock’s pluripotent stem cell-derived dopaminergic neuron therapy, is under evaluation in a Phase 1 study.
The FDA’s Fast Track designation is intended to facilitat
BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer?AG, announced?today?that Emile Nuwaysir, Ph.D., current President and CEO, will transition to the position of BlueRock Board Chair, effective August 1, 2021. Current Chief Scientific Officer Seth Ettenberg, Ph.D., will assume the role of President and CEO. BlueRock will continue in its mission to create authentic cellular medicines to reverse devastating diseases and improv
BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced today the dose administration for the first patient in a Phase 1 (Ph1), open-label study of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson’s disease (PD). The purpose of the Ph1 clinical trial is to evaluate the safety, tolerability, and preliminary efficacy of DA01 in patients wi
BlueRock Therapeutics LP, a leading engineered cell therapy company and a wholly-owned and independently operated subsidiary of Bayer AG, and Senti Biosciences, Inc. (Senti Bio), a leading gene circuit company, today announced a collaboration and option agreement to apply Senti Bio’s gene circuit technology to the development of BlueRock’s next-generation engineered cell therapies for a potentially broad array of therapeutic areas, inc
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, FUJIFILM Cellular Dynamics, Inc. a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, and Opsis Therapeutics, LLC, a joint venture of FUJIFILM Cellular Dynamics (FCDI) and David Gamm, M.D., Ph.D., co-founder, focusing on developing cell therapies for patients with ocular diseas
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced that Health Canada has given permission to initiate “Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson’s Disease (PD).” This is the first trial in Canada to study pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson’s disea
Ncardia and BlueRock Therapeutics today announced an agreement covering process development technologies for the manufacture of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. Under the terms of the agreement, Bluerock gains access to Ncardia’s large-scale production processes and intellectual property for the production of iPSC-derived cardiomyocytes for therapeutic use.
“BlueRock is a leader in the field of cell therapy an
BlueRock Therapeutics, a preclinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, in collaboration with Memorial Sloan Kettering Cancer Center (MSK), announced today that the U.S. Food and Drug Administration (FDA) has cleared their Investigational New Drug (IND) application to proceed with a Phase 1 (Ph1) study in patients with advanced Parkinson’s disease (PD). This